Immunovant Inc Stock Price, News & Analysis

On September 21, 2022, Immunovant (Nasdaq: IMVT) announced that CEO Pete Salzmann will present a corporate update at Roivant’s Investor Day on September 28, 2022, at 11:15 AM ET. The event will include a webcast available on the company's website. Immunovant focuses on developing therapies for autoimmune diseases and is known for its investigational compound, batoclimab, a monoclonal antibody targeting FcRn. The company aims to meet significant unmet patient needs in this sector.

Immunovant, a clinical-stage biopharmaceutical company focused on autoimmune diseases, announced that CEO Pete Salzmann will participate in a fireside chat at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, 2022. The chat is scheduled for September 14 at 4:00 PM Eastern Time. Interested parties can access the presentation via a webcast on the company’s website. Immunovant is developing innovative therapies, including the investigational compound batoclimab, a fully human monoclonal antibody targeting the neonatal Fc receptor (FcRn).

Immunovant (Nasdaq: IMVT) plans to initiate a pivotal Phase 2b trial for batoclimab in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in late 2022, with expected results from an open-label period by early 2024. A Phase 2 trial for Graves’ Disease is set for early 2023, with results anticipated later that year. The company expects a steady stream of clinical data every six months from late 2023 through early 2025, encompassing multiple indications. Immunovant continues to pursue batoclimab's development across five autoimmune conditions.

Immunovant, Inc. (Nasdaq: IMVT) has announced plans to advance the development of batoclimab for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Graves' Disease. A pivotal Phase 2b trial for CIDP is set to begin in late 2022, with initial results from an open-label period expected in early 2024. A Phase 2 trial for Graves’ Disease will start in early 2023, with results anticipated in late 2023. Immunovant aims for regular clinical data readouts every six months from late 2023 to early 2025, covering multiple indications, including Myasthenia Gravis and Thyroid Eye Disease.

Immunovant, a clinical-stage biopharmaceutical company focused on autoimmune diseases, will host a webcast on September 7, 2022 at 8:00 AM ET to announce two new indications for batoclimab. The event will feature remarks from company management and external key opinion leaders, followed by a live Q&A session. Interested participants can register for the webcast here. An archived recording will be available on the company's website afterward.

Immunovant, focused on autoimmune diseases, reported its financial results for Q1 fiscal 2022, ending June 30, 2022. Key updates include the initiation of a pivotal trial for batoclimab in Myasthenia Gravis, with top-line data expected in 2024. Two pivotal trials for Thyroid Eye Disease are planned for the second half of 2022. Financially, the company incurred $31 million in cash payments due to clinical trial costs. The cash balance stood at $427 million, anticipated to last into 2025. Net loss was $40.4 million, reflecting increased R&D and G&A expenses.

Immunovant (Nasdaq: IMVT) plans to start two Phase 3 trials for batoclimab in thyroid eye disease (TED) by late 2022, with top-line results expected in the first half of 2025. The U.S. TED patient market is estimated at 8,000-18,000. The company has a cash balance of $494 million as of March 31, 2022, ensuring operational funding into 2025. R&D expenses surged to $32 million in Q4 2022, while FY 2022 losses grew to $156.7 million. The firm is also set to initiate a Phase 3 trial in myasthenia gravis (MG) by June 2022.

Immunovant, Inc. (Nasdaq: IMVT) will release its fourth quarter and full-year 2022 financial results on June 8, 2022, before U.S. market open. The company will also host a conference call and webcast at 8:00 AM ET the same day, featuring a question-and-answer session for investors. Immunovant focuses on therapies for autoimmune diseases, particularly its investigational compound, batoclimab, a monoclonal antibody targeting the neonatal Fc receptor (FcRn). This information can be accessed via their investor relations website.

Immunovant (Nasdaq: IMVT) announced on May 23, 2022, that CEO Pete Salzmann will participate in a fireside chat at the H.C. Wainwright Global Investment Conference from May 23-26, 2022.

The chat is scheduled for May 25 at 12:30 pm ET and will be available via webcast on the company's Investor Relations page at www.immunovant.com.

Immunovant focuses on developing innovative therapies for autoimmune diseases, notably their investigational compound, batoclimab.